Contents

Search

Beyaz

FDA-approved 09/2010. - a combination of Yaz (monophasic oral contraceptive) & levomefolate Ca+2 (a folate) Indications: - to raise folate levels for the purpose of reducing risk of neural tube defect in a pregnancy conceived while taking Beyaz or shortly after discontinuing the it Pharmacokinetics: - increases folate levels in women - folate levels remained elevated for several weeks following discontinuation of Beyaz Note: - it seems as if the oral contraceptive is effective, there is little risk of neural tube defects in a fetus

General

monophasic oral contraceptive

References

  1. FDA News Release, Sept. 24, 2010 FDA approves combination contraceptive containing a folate
  2. Prescriber's Letter 17(12): 2010 Beyaz - An Oral Contraceptive with Folate Detail-Document#: 261207 (subscription needed) http://www.prescribersletter.com